Develops therapies for hypercholesterolemia and other cardiometabolic disorders by targeting lipid metabolism pathways to reduce cardiovascular risk.
Esperion Therapeutics, Inc. is a pharmaceutical company dedicated to developing and bringing to market innovative treatments for patients with elevated low density lipoprotein cholesterol (LDL-C). Specializing in cardiovascular health, Esperion focuses on advancing therapies that address unmet medical needs in atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Their flagship products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets, exemplify their commitment to providing effective solutions for these conditions.
In addition to its proprietary drug candidates, Esperion Therapeutics collaborates extensively within the industry. The company holds a strategic license and collaboration agreement with Daiichi Sankyo Europe GmbH, enhancing its global reach and capabilities in cardiovascular medicine. Furthermore, Esperion has partnered with Serometrix to license an oral, small molecule PCSK9 inhibitor program, bolstering its pipeline of potential therapies aimed at further reducing LDL-C levels.
Founded in 2008 and headquartered in Ann Arbor, Michigan, Esperion Therapeutics, Inc. continues to expand its portfolio and pursue advancements in lipid management therapies. With a steadfast commitment to scientific innovation and patient-centered care, Esperion remains at the forefront of developing transformative treatments for cardiovascular health challenges worldwide.